Abstract PS1-10-27: Progression-free survival (PFS) and overall survival (OS) results from the phase 3 MONALEESA-3 trial of postmenopausal patients with hormone receptor-positive (HR+)/HER2-negative (HER2−) advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL): A subgroup analysis of patients with invasive lobular carcinoma (ILC)
Year: 2026
Type: conference-abstract
Source: Clinical Cancer Research
Institutions: Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", The University of Texas MD Anderson Cancer Center, Seoul National University, Seoul National University Hospital, BC Cancer Agency, Universitätsklinikum Tübingen, Clinique Clémentville, University of Liège, Centre Hospitalier Universitaire de Liège, Novartis (Switzerland), Novartis (United States), Highlands Oncology Group
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7129470263
Cites:
Cited by:
Related to: